Press coverage about Anthera Pharmaceuticals (NASDAQ:ANTH) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Anthera Pharmaceuticals earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.8985679975274 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

ANTH has been the topic of a number of recent research reports. ValuEngine raised Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research raised Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research report on Tuesday, October 10th. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Anthera Pharmaceuticals in a research report on Tuesday, September 19th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $1.75 target price (down from $2.25) on shares of Anthera Pharmaceuticals in a research report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $5.11.

Anthera Pharmaceuticals (ANTH) traded up 2.1730% during midday trading on Friday, reaching $1.6551. The company’s stock had a trading volume of 116,347 shares. The firm’s market cap is $18.05 million. Anthera Pharmaceuticals has a 52 week low of $1.20 and a 52 week high of $2.83. The firm has a 50 day moving average price of $1.52 and a 200-day moving average price of $1.44.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.09) by $1.12. On average, analysts forecast that Anthera Pharmaceuticals will post ($3.68) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/20/anthera-pharmaceuticals-anth-earns-daily-media-impact-score-of-0-07.html.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Insider Buying and Selling by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Stock Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.